C3N-00555
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 59.60574949
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.580
- MYC_TARGETS_V1+0.530
- OXIDATIVE_PHOSPHORYLATION+0.520
- E2F_TARGETS+0.430
- G2M_CHECKPOINT+0.410
- SPERMATOGENESIS+0.360
- DNA_REPAIR+0.330
- MTORC1_SIGNALING+0.300
- FATTY_ACID_METABOLISM+0.270
- UNFOLDED_PROTEIN_RESPONSE+0.250
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.480
- UV_RESPONSE_DN-0.410
- INTERFERON_GAMMA_RESPONSE-0.390
- NOTCH_SIGNALING-0.380
- TGF_BETA_SIGNALING-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- IL6_JAK_STAT3_SIGNALING-0.320
- KRAS_SIGNALING_UP-0.300
- INFLAMMATORY_RESPONSE-0.290
- COMPLEMENT-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-33-4532-01A-01R-1201-07 | — | cohortSQ2 | 0.930 |
| 2 | AUR-AFUM-TTM1-A-1-1-R-A743-41 | — | E | 0.921 |
| 3 | TCGA-56-8304-01A-11R-2326-07 | — | cohortSQ1 | 0.916 |
| 4 | TCGA-85-8354-01A-31R-2326-07 | — | cohortSQ2 | 0.904 |
| 5 | C3L-00993 | — | cohortSQ1 | 0.898 |
| 6 | SRR6013549 | — | cohortSQ2 | 0.894 |
| 7 | TCGA-33-4582-01A-01R-1443-07 | — | cohortSQ2 | 0.891 |
| 8 | MBCProject_4634_T1_RNA | — | E | 0.887 |
| 9 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.886 |
| 10 | ERR2208894 | — | — | 0.886 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.580 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.520 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.360 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.330 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| PEROXISOME | 0.140 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.060 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.020 | Inavolisib | — uncovered |